Lifevantage (NASDAQ:LFVN) Releases Earnings Results

Lifevantage (NASDAQ:LFVN) released its quarterly earnings data on Tuesday. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.01, Zacks reports. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. Lifevantage updated its FY 2026 guidance to 1.000-1.150 EPS.

Lifevantage Trading Down 4.6%

LFVN traded down $0.34 during midday trading on Tuesday, reaching $7.00. The company’s stock had a trading volume of 331,180 shares, compared to its average volume of 187,016. The firm has a market capitalization of $88.84 million, a price-to-earnings ratio of 9.46 and a beta of 0.26. Lifevantage has a 1 year low of $6.97 and a 1 year high of $27.38. The stock’s 50-day moving average is $10.13 and its 200-day moving average is $11.85.

Lifevantage Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 16th. Shareholders of record on Monday, September 8th were issued a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Monday, September 8th. Lifevantage’s dividend payout ratio is 24.32%.

Analyst Ratings Changes

LFVN has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Lifevantage in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Lifevantage from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.50.

Insiders Place Their Bets

In related news, Director Michael A. Beindorff sold 4,125 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $11.44, for a total transaction of $47,190.00. Following the sale, the director directly owned 22,858 shares of the company’s stock, valued at approximately $261,495.52. This represents a 15.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 21.95% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after acquiring an additional 4,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Lifevantage during the second quarter valued at $76,000. BNP Paribas Financial Markets increased its holdings in Lifevantage by 2,555.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock worth $80,000 after buying an additional 5,904 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Lifevantage during the 1st quarter valued at about $97,000. Finally, New York State Common Retirement Fund bought a new position in Lifevantage during the 2nd quarter valued at about $102,000. Institutional investors own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.